Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soriot Makes Changes At AstraZeneca As The Pharma Explores Its Options

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca’s Soriot makes big moves on his first day on the job – putting a hold on the company’s share-repurchase program and causing speculation that a big acquisition is set for the near future.

Advertisement

Related Content

AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub
AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division
Brennan’s Abrupt Departure Has Some Viewing AstraZeneca As A Buyout Target
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
Amgen Gets Cost-Sharing, MedImmune A Pipeline Boost In Five-Antibody Collaboration
AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
AstraZeneca To Lay Off 24% Of U.S. Sales Force As Of Feb. 2012

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel